|
THE ALZHEIMER'S DRUG DISCOVERY FOUNDATION
COMMEMORATES TWELTH ANNUAL FALL SYMPOSIUM AND LUNCHEON
The ADDF Celebrates a Decade of Leadership
and Support by Howard & Mitchell Kaneff
The Alzheimer's Drug Discovery Foundation (ADDF) hosted its
12th Annual Fall Symposium and Luncheon virtually
on Thursday, October 28, raising $1.2M for drug development
research to prevent, treat, and cure Alzheimer's disease.
Hosted by nine-time Emmy Award winner,
journalist, and ADDF board member Paula Zahn, the virtual
celebration honored Howard Kaneff, Chairman Emeritus, and
Mitchell Kaneff, Chairman and CEO, of Arkay Packaging with
the Charles Evans Award for Leadership and awarded the
Melvin R. Goodes Prize to Miia Kivipelto, MD, PhD, Professor
in Clinical Geriatrics at Karolinska Institutet, Center for
Alzheimer Research and senior geriatrician and Director for
Research & Development of Theme Aging at Karolinska
University Hospital, Stockholm, Sweden. The virtual event
featured ADDF Co-Founders and Co-Chairmen Leonard A. Lauder
and Ronald S. Lauder.
Howard and Mitchell Kaneff Honored with
the 2021 Charles Evans Award for Leadership
The Charles Evans Award was presented to
Howard and Mitchell Kaneff for their leadership in support
of the prevention, treatment, and cure of Alzheimer’s
disease. Arkay is a three-generation family-run business
that has provided packaging for the cosmetics,
pharmaceutical, and health and beauty industries, including
Estee Lauder Companies, for over nine decades. Howard and
Mitchell are both esteemed supporters of the ADDF, and
Mitchell currently serves on the ADDF’s Board of Overseers.
Leonard Lauder offered praise for the Kaneffs
and their decades of support. “I’ve known Howard and
Mitchell for several decades, both as dear friends and
respected business partners. When Howard’s late wife and
Mitchell’s mother, Cherry, started experiencing Alzheimer’s
symptoms, there was no definitive way to receive a
diagnosis. Thanks to the ADDF and support of steadfast
supporters, like the Kaneffs, that is no longer the case –
we now have the diagnostic tools to provide patients and
families with the answers they deserve.”
“I'm incredibly honored and humbled, as I
know my father is, to accept the 2021 Charles Evans Award,”
said Mitchell. “As an ADDF board member and someone whose
lost a loved one to Alzheimer’s, I am grateful to be part of
an organization that is playing a key role in driving
progress in new diagnostic tools and therapies.”
“When I heard that we were going to receive
the Charles Evans Award, I was thrilled,” added Howard. “I
first became acquainted with the ADDF through my dear
friend, Leonard Lauder, over twenty years ago and today, my
son is on the board and playing a key role in raising
financial support to further critical research.”
Dr. Miia Kivipelto Awarded the 2021
Melvin R. Goodes Prize for Innovative Research
The 2021 Melvin R. Goodes Prize, an annual
award given by the ADDF to leading researchers making
important strides towards the development of effective
treatments and a cure for Alzheimer’s, was awarded to Dr.
Kivipelto. The Goodes
Prize was established in 2015 by Mel, an honorary member
of ADDF’s Board of Governors and Nancy Goodes, a member of
the ADDF’s Board of Governors.
The Goodes Prize includes a $150,000 award
and will support Dr. Kivipelto’s continued research on
prevention, early diagnosis and treatment of cognitive
impairment, dementia, and Alzheimer’s disease.
Introducing the award, Nancy Goodes said,
“When we first launched the Goodes Prize, our goal was to
honor Mel and his legacy in the drug development field,
while also supporting cutting-edge science championed by the
ADDF, and this award does just that. We are delighted to
present this year’s Goodes Prize to Dr. Kivipelto, whose
monumental work with the FINGER trial has transformed how we
view lifestyle interventions for Alzheimer’s prevention.”
Dr. Kivipelto expressed her gratitude for the
honor, “On behalf of my team and me, I am incredibly honored
to receive such prestigious recognition, which also provides
validation for the multidomain prevention model that targets
both several risk factors and mechanisms. This award is
especially significant as Mel Goodes, a prominent leader in
the pharmaceuticals industry, and his work positively
impacted numerous patients. Receiving an award in Mel and
Nancy’s name is an inspiration as we continue with our
research into the prevention of Alzheimer’s.”
Dr. Kivipelto joined another remarkable
scientist at the annual symposium. Moderated by the ADDF’s
Founding Executive Director and Chief Science Officer, Dr.
Howard Fillit, Dr. Kivipelto was joined by Miranda Orr, PhD
and Assistant Professor of Gerontology and Geriatric
Medicine at the Wake Forest School of Medicine for a panel
titled The State of Alzheimer’s
Prevention: What Can You Do Today?
The Fall Symposium and Luncheon would not
have been possible without the generous support of many
contributors and donors: including: Melanie Goodes Caceres,
The Estée Lauder Companies Inc., Nancy and Melvin R. Goodes,
Kiera and Christopher Johnson, Howard Kaneff, Mitchell
Kaneff, Judy and Leonard A. Lauder, Gary and Laura Lauder,
William P. Lauder and Lori Kanter Tritsch, Jo Carole and
Ronald S. Lauder, Susan and Tom Lowder, Samuel I. Newhouse
Foundation, Sharon T. Sager and J. Loring Swasey, Liz and
Randal Sandler, and David R. Weinreb.
The ADDF also acknowledges Lilly for
underwriting the Scientific Symposium portion of the event.
The full event can be enjoyed online here.
About the Alzheimer's Drug Discovery
Foundation
Founded in 1998 by Leonard A. Lauder
and Ronald S. Lauder, the Alzheimer's Drug Discovery
Foundation is dedicated to rapidly accelerating the
discovery of drugs to prevent, treat and cure Alzheimer's
disease. The ADDF is the only public charity solely focused
on funding the development of drugs for Alzheimer's,
employing a venture philanthropy model to support research
in academia and the biotech industry. Through the generosity
of its donors, The ADDF has granted more than $168 million
to fund over 650 programs for Alzheimer's and related
dementias in academic centers and biotechnology companies in
19 countries. To learn more, please visit
www.alzdiscovery.org
|